DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services" report to their offering.
According to this latest report, "PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a boom or bust proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity.
Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.
- Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.
Reasons to buy
- CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking
- Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence
- Private equity: investment targeting, portfolio company performance benchmarking
Key Topics Covered:
1 Table of Contents
2 Executive Summary
3 Context and Objectives
4 Clinical Trial Activity of Emerging Bio/Pharma Companies
5 Clinical Development Costs and Spending by Emerging Bio/Pharma Companies
6 External Financing for Emerging Bio/Pharma Companies
7 Outlook and What it Means
For more information about this report visit http://www.researchandmarkets.com/research/kkltc9/pharmsource